U.S. market Closed. Opens in 11 hours 36 minutes

NRIX | Nurix Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-11-302022-11-302021-11-302020-11-302019-11-302018-11-30
Revenue76.99M38.63M29.75M17.82M31.11M37.45M
Cost of Revenue13.65M10.81M6.08M66.49M45.02MN/A
Gross Profit63.33M27.82M23.67M-48.67M-13.91M37.45M
Operating Expenses218.40M222.49M147.64M82.80M53.35M47.19M
Selling, General & Admin36.78M38.00M31.20M16.31M8.33M6.67M
Research & Development181.62M184.50M116.43M66.49M45.02M40.51M
Other Operating ExpensesN/AN/AN/AN/AN/AN/A
Operating Income-155.06M-183.87M-117.89M-64.98M-22.24M-9.74M
Other Expenses / Income11.12M3.51M823.00K1.21M776.00K818.00K
Before Tax Income-143.95M-180.36M-117.06M-63.78M-21.46M-8.92M
Income Tax Expenses13.49M-14.31M131.00K-20.54M239.00K507.00K
Net Income-143.95M-166.04M-117.19M-43.24M-21.70M-9.43M
Interest ExpensesN/A-14.31MN/AN/AN/A-818.00K
Basic Shares Outstanding54.34M48.61M42.90M15.67M38.85M16.11M
Diluted Shares Outstanding54.34M48.61M42.90M15.67M38.85M16.11M
EBITDA-141.41M-183.87M-117.89M-64.98M-19.88M-6.75M
EBITDA Margin-183.68%-476.01%-396.26%-364.66%-63.90%-18.03%
EBIT-130.46M-194.68M-117.06M-63.78M-21.46M-9.74M
EBIT Margin-169.46%-503.99%-393.49%-357.90%-68.97%-26.01%
Financial Year End2023-11-302022-11-302021-11-302020-11-302019-11-302018-11-30
An error has occurred. This application may no longer respond until reloaded. Reload 🗙